Looking for Sentiment Analysis? Discover the most popular stocks on Reddit by using our Sentiment Tracker
Market Cap 3.43B P/E - EPS this Y -21.70% Ern Qtrly Grth -
Income -179.33M Forward P/E -12.41 EPS next Y -10.60% 50D Avg Chg 2.00%
Sales - PEG - EPS past 5Y - 200D Avg Chg 32.00%
Dividend N/A Price/Book 8.71 EPS next 5Y - 52W High Chg -13.00%
Recommedations 1.40 Quick Ratio 7.47 Shares Outstanding 41.31M 52W Low Chg 120.00%
Insider Own 9.33% ROA -41.69% Shares Float 31.42M Beta -
Inst Own 91.01% ROE -74.36% Shares Shorted/Prior 2.31M/2.33M Price 75.80
Gross Margin - Profit Margin - Avg. Volume 238,228 Target Price 72.14
Oper. Margin - Earnings Date Mar 25 Volume 170,175 Change -2.23%
Zentalis Pharmaceuticals, Inc. News
11/17/21 Zentalis Pharmaceuticals Insider Sold Over $750K In Company Stock
11/17/21 Zentalis Pharmaceuticals Announces Fast Track Designation Granted by the U.S. FDA to ZN-c3 for the Treatment of Uterine Serous Carcinoma
11/10/21 Zentalis Pharmaceuticals Reports Third Quarter 2021 Financial Results and Operational Update
11/09/21 Zentalis Pharmaceuticals to Present at Two Upcoming Investor Conferences
11/08/21 Director Of Zentalis Pharmaceuticals Makes $830K Sale
11/03/21 Zentalis Pharmaceuticals Insider Trades $1.7M In Company Stock
10/25/21 Hedge Funds Are Piling Into Zentalis Pharmaceuticals, Inc. (ZNTL)
10/05/21 Zentalis Pharmaceuticals Insider Trades $1.8M In Company Stock
09/13/21 Zentalis Pharmaceuticals Announces First Patient Dosed in the Phase 1/2 Study of ZN-c3 in Combination with Gemcitabine in Patients with Osteosarcoma
09/09/21 Zentalis Pharmaceuticals to Present at the European Society for Medical Oncology (ESMO) Congress 2021
09/02/21 Zentalis Pharmaceuticals to Participate in Two Upcoming Investor Conferences
09/01/21 Zentalis Pharmaceuticals Announces Publication in the Journal of Medicinal Chemistry Highlighting the Discovery of its WEE1 Inhibitor Candidate ZN-c3
08/12/21 Zentalis Pharmaceuticals Reports Second Quarter 2021 Financial Results and Operational Update
08/04/21 Zentalis Pharmaceuticals to Participate in the Wedbush PacGrow Healthcare Virtual Conference
08/02/21 Zentalis Pharmaceuticals Announces First Patient Dosed in Potentially Registrational Phase 2 Study of ZN-c3 in Patients with Uterine Serous Carcinoma
08/02/21 Zentera Therapeutics Announces Closing of $75 Million Series B Financing
07/28/21 Is ZNTL Stock A Buy or Sell?
07/01/21 Zentalis Pharmaceuticals Announces Closing of Offering of Common Stock and Full Exercise of Underwriters’ Option to Purchase Additional Shares
06/29/21 Zentalis Secures $150M In Equity Funding

Zentalis Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focuses on discovering and developing small molecule therapeutics for the treatment of various cancers. Its lead product candidates are the ZN-c5, an oral selective estrogen receptor degrader that is in a Phase 1/2 clinical trial for the treatment of advanced estrogen receptor-positive, human epidermal growth factor receptor 2-negative, or advanced or metastatic breast cancer; and ZN-c3, an inhibitor of WEE1, a protein tyrosine kinase, which is in Phase 1/2 clinical trial for the treatment of advanced solid tumors, as well as in Phase 1b clinical trial in combination with chemotherapy in patients with advanced ovarian cancer. The company also develops ZN-d5, a selective inhibitor of B-cell lymphoma 2 that is in a Phase 1 clinical trial for the treatment of non-Hodgkin's lymphoma and acute myelogenous leukemia; and ZN-e4, an irreversible inhibitor of mutant epidermal growth factor receptor, which is in Phase 1/2 clinical trial for the treatment of advanced non-small cell lung cancer. Zentalis Pharmaceuticals has licensing agreements and strategic collaborations with Recurium IP Holdings, LLC; Mayo Foundation for Medical Education and Research; SciClone Pharmaceuticals International (Cayman) Development Ltd.; Pfizer, Inc.; Eli Lilly and Company; and Zentera Therapeutics (Cayman), Ltd. The company was incorporated in 2014 and is based in New York, New York.

ZNTL Chatroom

User Image TickrTalk12 Posted - 1 day ago

$ZNTL turn will be $15

User Image Insider_Analysis Posted - 2 days ago

$ZNTL Kevin D. Bunker sold 10,000 shares [High Conviction] www.insider-analysis.com/search_transactions.php?ticker=TABLE_ZNTL

User Image TickrTalk12 Posted - 3 days ago

$ZNTL 🐩 💩

User Image macroaxis Posted - 3 days ago

$ZNTL - Zentalis Pharmaceuticals exotic insider… https://www.macroaxis.com/invest/story/ZNTL/22923820/Zentalis-Pharmaceuticals-exotic-insider-transaction-detected #insidertrading #stocks #fintechnews

User Image MarketBeatInsiderTrades Posted - 3 days ago

Zentalis Pharmaceuticals COO Kevin Bunker Sells $759,900.00 in $ZNTL https://www.marketbeat.com/i/484146

User Image cctranscripts Posted - 3 days ago

Zentalis Pharmaceuticals, Inc.'s Chief Operating Officer just disposed of 10,000 shares https://www.conferencecalltranscripts.com/summary/?id=10146710 $ZNTL

User Image risenhoover Posted - 3 days ago

Insider Bunker Kevin D. reports selling 10,000 shares of $ZNTL for a total cost of $759,937.00 https://fintel.io/n/us/zntl/bunker-kevin-d?utm_source=stocktwits.com&utm_medium=Referral&utm_campaign=insider

User Image fla Posted - 3 days ago

$ZNTL [15s. delayed] filed SEC form 4: Chief Operating Officer Bunker Kevin D.: Disposed 10,000 of Common Stock at price $75.99 on 2021-1 https://s.flashalert.me/Q91n3

User Image Quantisnow Posted - 3 days ago

$ZNTL 📜 SEC Form 4: Bunker Kevin D. sold $759,937 worth of shares (10,000 units at $75.99) as part of a pre-agreed trading plan https://quantisnow.com/insight/2048938?s=s 45 seconds delayed.

User Image Newsfilter Posted - 3 days ago

$ZNTL $759,900.00 of shares sold by Bunker Kevin D. (Chief Operating Officer), reported in a new form 4 filed with the SEC https://newsfilter.io/a/24a872b107fae0c1e3558042a3ea6333

User Image T8skmod Posted - 4 days ago

$ZNTL Twits Stats Today's Change 15% + 🚀 https://t8sk.com/ZNTL

User Image tickeron Posted - 5 days ago

How will this affect the market? $ZNTL in Downtrend: its price may decline as a result of having broken its higher Bollinger Band on November 3, 2021. View odds for this and other indicators: https://srnk.us/go/3176553

User Image Tickstocks Posted - 1 week ago

$ZNTL Twits Stats Today's Change 15% + 🚀 https://t8sk.com/ZNTL

User Image SweepCast Posted - 1 week ago

SweepCast alerted: $ZNTL with Unusual Options Activity Alerted on $75 PUT Expiring: 01-21-2022 worth 128K🐻 |🥇 Learn How Unusual Options Helps Gain Insights! www.sweepcast.com 🥇 |

User Image T8skmod Posted - 1 week ago

$ZNTL Twits Stats Today's Change 15% + 🚀 https://t8sk.com/ZNTL

User Image Stockgrid Posted - 1 week ago

Unusual Option Alert on $ZNTL $128,050 put block traded with $75.0 strike expiring on 2022-01-21. Via: https://www.stockgrid.io/optionsflow-dashboard/ZNTL

User Image Insider_Analysis Posted - 1 week ago

$ZNTL Cam Gallagher sold 10,000 shares [High Conviction] www.insider-analysis.com/search_transactions.php?ticker=TABLE_ZNTL

User Image itsallaboutheoptions Posted - 1 week ago

$ZNTL Zentalis Pharma (ZNTL) receives Fast Track Designation for ZN-c3 from FDA

User Image cctranscripts Posted - 1 week ago

On November https://www.conferencecalltranscripts.com/summary/?id=10125651 $ZNTL

User Image Quantisnow Posted - 1 week ago

$ZNTL 📜 Zentalis Pharmaceuticals, Inc. filed SEC Form 8-K: Other Events https://quantisnow.com/insight/2025372?s=s 45 seconds delayed.

User Image fla Posted - 1 week ago

$ZNTL [15s. delayed] filed form 8-K on November 17, 17:15:54 https://s.flashalert.me/t4YNr

User Image risenhoover Posted - 1 week ago

$ZNTL / Zentalis Pharmaceuticals files form 8-K - UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): November 17, 2021 ZENTALIS PHARMA https://fintel.io/sf/us/zntl?utm_source=stocktwits.com&utm_medium=Referral&utm_campaign=filing

User Image MarketNewswire Posted - 1 week ago

$ZNTL New SEC Filing: 8-K Other Events - Zentalis Pharmaceuticals, Inc. (0001725160) November 17 Item 8.01. Other Events.On November 17, 2021, Zentalis Pharmaceuticals, Inc. (the "Company") announced that the U.S. Food and Drug Administration (FDA) has granted Fast Track designation to ZN-c3, the Company's oral WEE1 inhibitor product candidate, for the treatment of recurrent or persistent uterine serous carcinoma (USC) in adult women. SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. ZENTALIS PHARMACEUTICALS, INC.Date: November 17, 2021 By: /s/ Anthony Y. Sun, M.D. Anthony Y. Sun, M.D. President and Chief Executive Officer (...) https://marketnewswire.live?p=179134

User Image Newsfilter Posted - 1 week ago

$ZNTL Form 8-K: On November 17, 2021, Zentalis Pharmaceuticals announced that the U.S. Food and Drug Administration has granted Fast Track designation to ZN-c3, the Company’s oral WEE1 inhibitor produ.. https://newsfilter.io/a/2e958dda492b8fe2a275d33a72745d83

User Image T8skmod Posted - 1 week ago

$ZNTL Twits Stats Today's Change 15% + 🚀 https://t8sk.com/ZNTL

User Image briefingcom Posted - 1 week ago

$ZNTL receives Fast Track Designation for ZN-c3 from FDA https://www.briefing.com/in-depth-analysis/Content/Article?ArticleId=IN20211117070548ZNTL

User Image cctranscripts Posted - 1 week ago

Zentalis Pharmaceuticals Announces Fast Track Designation Granted by the U.S. FDA to ZN-c3 for the Treatment of Uterine Serous Carcinoma https://conferencecalltranscripts.com/summary/?id=331676&pr=true $ZNTL

User Image fla Posted - 1 week ago

$ZNTL [15s. delayed]: Issued Press Release on November 17, 07:00:00: Zentalis Pharmaceuticals Announces Fast Track Designation Granted by https://s.flashalert.me/rA5UU

User Image Quantisnow Posted - 1 week ago

$ZNTL 📰 Zentalis Pharmaceuticals Announces Fast Track Designation Granted by the U.S. FDA to ZN-c3 for the Treatment of Uterine Serous Carcinoma https://quantisnow.com/insight/2020526?s=s 45 seconds delayed.

User Image Newsfilter Posted - 1 week ago

$ZNTL Zentalis Pharmaceuticals Announces Fast Track Designation Granted by the U.S. FDA to ZN-c3 for the Treatment of Uterine Serous Carcinoma https://newsfilter.io/a/9e5bd4b55af42abd16b876c11a94c550

Analyst Ratings
UBS Buy May 20, 21
HC Wainwright & Co. Buy May 18, 21
SVB Leerink Outperform Apr 12, 21
HC Wainwright & Co. Buy Mar 25, 21
Wedbush Outperform Jan 19, 21
Morgan Stanley Overweight Dec 15, 20
Morgan Stanley Overweight Nov 10, 20
Cantor Fitzgerald Overweight Sep 28, 20
HC Wainwright & Co. Buy Aug 26, 20
Insider Trades Relationship Date Transactions Cost($) #Shares Value($) #Share Own SEC Form 4
Gallagher Cam Director Director Nov 05 Sell 82.95 10,000 829,500 447,203 11/05/21
Blackwell Kimberly Director Director Nov 01 Option 47.8 1,000 47,800 6,000 11/02/21
Blackwell Kimberly Director Director Nov 01 Sell 80.46 1,000 80,460 5,000 11/02/21
Blackwell Kimberly Director Director Oct 25 Option 47.8 1,000 47,800 6,000 10/27/21
Blackwell Kimberly Director Director Oct 25 Sell 77.59 1,000 77,590 5,000 10/27/21
Pinto Alexis Chief Legal Officer Chief Legal Officer Oct 25 Option 34.4 30,000 1,032,000 36,526 10/27/21
Pinto Alexis Chief Legal Officer Chief Legal Officer Oct 25 Sell 77.57 30,000 2,327,100 6,526 10/27/21
Gallagher Cam Director Director Sep 02 Sell 67.62 10,000 676,200 467,203 09/02/21
SUN ANTHONY Y President & CEO President & CEO Sep 02 Sell 67.83 26,794 1,817,437 1,297,342 09/02/21
Bunker Kevin D. Chief Operating Offi.. Chief Operating Officer Sep 02 Sell 67.81 8,420 570,960 8,420 09/02/21
Epperly Melissa B, Chief Financial Offi.. Chief Financial Officer Aug 20 Buy 52 9,611 499,772 266,685 08/20/21
SUN ANTHONY Y President & CEO President & CEO Jul 08 Sell 47.32 42,849 2,027,615 1,350,930 07/08/21
Gallagher Cam Director Director Jun 02 Sell 54.29 10,000 542,900 515,573 06/02/21
Bunker Kevin D. Chief Operating Offi.. Chief Operating Officer Jun 02 Sell 54.43 8,420 458,301 33,680 06/02/21
Epperly Melissa B, Chief Financial Offi.. Chief Financial Officer Jun 02 Sell 54.45 3,083 167,869 260,157 06/02/21
SUN ANTHONY Y President & CEO President & CEO Jun 02 Sell 54.33 26,794 1,455,718 1,420,573 06/02/21
Bunker Kevin D. Chief Operating Offi.. Chief Operating Officer Apr 05 Sell 43.96 4,210 185,072 54,730 04/05/21
Gallagher Cam Director Director Dec 08 Sell 54.05 36,739 1,985,743 580,192 12/08/20
Epperly Melissa B, Chief Financial Offi.. Chief Financial Officer Dec 08 Sell 52.23 13,684 714,715 277,679 12/08/20
Bunker Kevin D. Chief Operating Offi.. Chief Operating Officer Dec 08 Sell 52.23 23,057 1,204,267 1,053,880 12/08/20
SUN ANTHONY Y President & CEO President & CEO Dec 08 Sell 52.23 75,375 3,936,836 2,017,605 12/08/20
Johnson David Michael Director Director Dec 03 Buy 18 4,000 72,000 114,648 12/03/20
Johnson David Michael Director Director Dec 03 Sell 51.24 12,896 660,791 101,752 12/03/20
Bunker Kevin D. Chief Operating Offi.. Chief Operating Officer Dec 03 Sell 52.41 8,420 441,292 84,200 12/03/20
Gallagher Cam Director Director Dec 03 Sell 51.26 10,000 512,600 616,931 12/03/20
Epperly Melissa B, Chief Financial Offi.. Chief Financial Officer Nov 25 Buy 18 20,000 360,000 297,529 11/25/20
Epperly Melissa B, Chief Financial Offi.. Chief Financial Officer Nov 25 Sell 46.88 3,083 144,531 294,446 11/25/20
Bunker Kevin D. Chief Operating Offi.. Chief Operating Officer Nov 25 Buy 18 350 6,300 1,177,982 11/25/20
Bunker Kevin D. Chief Operating Offi.. Chief Operating Officer Nov 25 Sell 46.85 8,425 394,711 92,620 11/25/20
SUN ANTHONY Y President & CEO President & CEO Nov 25 Buy 18 888 15,984 2,146,568 11/25/20
SUN ANTHONY Y President & CEO President & CEO Nov 25 Sell 46.82 26,794 1,254,495 2,119,774 11/25/20
Gallagher Cam Director Director Nov 25 Sell 46.87 10,000 468,700 626,931 11/25/20